在皮肤冠状动脉干预中使用修饰:全面审查
Noyan Ramazani1, Ala W Abdallah2, Michael V DiCaro1,3
1Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas, NV 89119, USA.
Journal of clinical medicine
|November 27, 2025
概括
通过皮肤冠状动脉干预 (PCI) 治疗化冠状动脉病变是具有挑战性的. 本综述详细介绍了修饰技术,以提高程序的成功和患者的结果.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 结冠状动脉病变使皮肤冠状动脉干预 (PCI) 复杂化,增加了程序风险和不良事件.
- 挑战包括困难的设备交付,气球/支架扩张,以及更高的支架血栓形成,剖析和恢复率.
研究的目的:
- 审查冠状动脉化的病理生理学和表型.
- 讨论PCI中使用的各种修饰技术.
- 根据当前的指导方针和专家共识,评估每个技术的优点,局限性和证据.
主要方法:
- 文献综述侧重于冠状动脉化病理生理学和PCI技术.
- 对修饰方式的分析:气球血管造形术,血管内立体术,轨道切除术和旋转切除术.
- 从专家共识 (SCAI) 和指南中评估证据和建议.
主要成果:
- 冠心内成像改善了治疗化病变的外置手术成功率.
- 不同的化现象 (例如,古怪的斑块,化的结节) 需要量身定制的方法.
- 每种技术都有特定的优点和局限性,影响临床应用.
结论:
- 优化PCI的化病变需要了解病理生理学和选择适当的修饰技术.
- 目前的证据和专家的共识指导了不同化表型的选择方式.
- 综合性审查提供了对管理复杂化冠状动脉病变的当前指导方针的见解.
相关概念视频
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
374
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
374
Coronary Artery Disease V: Interprofessional Care
206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
Cardiac Catheterization I: Pre-Procedure Overview
1.0K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
1.0K
Angina IV: Management
222
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
222


